Deals Of The Week: Merck KGaA/Ono, Puma/Pfizer, AstraZeneca /MedImmune/Pfizer…
Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com.
You may also be interested in...
Two private equity firms’ agreement to acquire Pharmaceutical Product Development Inc. and take the company private is the latest and largest deal in a recent spate of PE activity among contract research organizations – and perhaps not the last, or even least.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.